Dynavax Technologies Corp has announced promising results for its shingles vaccine candidate, Z-1018, which demonstrated a favorable tolerability profile and robust immune responses in a Phase 1/2 clinical trial.

Dynavax Technologies Corp reports record revenue of $95.4 million in Q2 2025, exceeding analyst expectations and setting a positive tone for the company’s financial outlook.